FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001852593> ?p ?o ?g. }

• W2001852593 endingPage "1972" @default.
• W2001852593 startingPage "1964" @default.
• W2001852593 abstract "Abstract Purpose: NGR-hTNF exploits the tumor-homing peptide asparagine-glycine-arginine (NGR) for selectively targeting TNF-α to an aminopeptidase N overexpressed on cancer endothelial cells. Preclinical synergism with cisplatin was displayed even at low doses. This study primarily aimed to explore the safety of low-dose NGR-hTNF combined with cisplatin in resistant/refractory malignancies. Secondary aims included pharmacokinetics (PKs), pharmacodynamics, and activity. Experimental Design: NGR-hTNF was escalated using a doubling-dose scheme (0.2–0.4–0.8–1.6 μg/m2) in combination with fixed-dose of cisplatin (80 mg/m2), both given intravenously once every three weeks. PKs and circulating TNF-receptors (sTNF-Rs) were assessed over the first three cycles. Results: Globally, 22 patients (12 pretreated with platinum) received a range of one to ten cycles. Consistently with the low-dose range tested, maximum-tolerated dose was not reached. No dose-limiting toxicities (DLTs) were observed at 0.2 (n = 4) and 0.4 μg/m2 (n = 3). One DLT (grade 3 infusion-related reaction) was observed at 0.8 μg/m2. This dose cohort was expanded to six patients without further DLTs. No DLTs were noted also at 1.6 μg/m2 (n = 3). NGR-hTNF exposure increased dose-proportionally without apparent PK interactions with cisplatin. No shedding of sTNF-Rs was detected up to 0.8 μg/m2. At the dose level of 0.8 μg/m2, expanded to 12 patients for activity assessment, a platinum-pretreated lung cancer patient achieved a partial response lasting more than six months and five patients maintained stable disease for a median time of 5.9 months. Conclusions: The combination of NGR-hTNF 0.8 μg/m2 with cisplatin 80 mg/m2 showed favorable toxicity profile and promising antitumor activity. Clin Cancer Res; 17(7); 1964–72. ©2011 AACR." @default.
• W2001852593 created "2016-06-24" @default.
• W2001852593 creator A5009015207 @default.
• W2001852593 creator A5025322230 @default.
• W2001852593 creator A5031391013 @default.
• W2001852593 creator A5038305710 @default.
• W2001852593 creator A5040884103 @default.
• W2001852593 creator A5044577073 @default.
• W2001852593 creator A5045859251 @default.
• W2001852593 creator A5047052496 @default.
• W2001852593 creator A5052353123 @default.
• W2001852593 creator A5060440062 @default.
• W2001852593 creator A5062656872 @default.
• W2001852593 creator A5064646828 @default.
• W2001852593 creator A5067487266 @default.
• W2001852593 creator A5068715327 @default.
• W2001852593 creator A5079789461 @default.
• W2001852593 creator A5089880898 @default.
• W2001852593 creator A5090199263 @default.
• W2001852593 date "2011-03-31" @default.
• W2001852593 modified "2023-10-18" @default.
• W2001852593 title "Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors" @default.
• W2001852593 cites W1559937222 @default.
• W2001852593 cites W1848316250 @default.
• W2001852593 cites W1890068101 @default.
• W2001852593 cites W1975984380 @default.
• W2001852593 cites W1989084881 @default.
• W2001852593 cites W1991684762 @default.
• W2001852593 cites W1996715118 @default.
• W2001852593 cites W2009403054 @default.
• W2001852593 cites W2031583328 @default.
• W2001852593 cites W2036564049 @default.
• W2001852593 cites W2044717219 @default.
• W2001852593 cites W2057123987 @default.
• W2001852593 cites W2060458709 @default.
• W2001852593 cites W2065162646 @default.
• W2001852593 cites W2088657493 @default.
• W2001852593 cites W2090472525 @default.
• W2001852593 cites W2096704471 @default.
• W2001852593 cites W2102627969 @default.
• W2001852593 cites W2113433199 @default.
• W2001852593 cites W2120244004 @default.
• W2001852593 cites W2149396308 @default.
• W2001852593 cites W2159711942 @default.
• W2001852593 cites W4240420638 @default.
• W2001852593 doi "https://doi.org/10.1158/1078-0432.ccr-10-1376" @default.
• W2001852593 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21307147" @default.
• W2001852593 hasPublicationYear "2011" @default.
• W2001852593 type Work @default.
• W2001852593 sameAs 2001852593 @default.
• W2001852593 citedByCount "49" @default.
• W2001852593 countsByYear W20018525932012 @default.
• W2001852593 countsByYear W20018525932013 @default.
• W2001852593 countsByYear W20018525932014 @default.
• W2001852593 countsByYear W20018525932015 @default.
• W2001852593 countsByYear W20018525932016 @default.
• W2001852593 countsByYear W20018525932017 @default.
• W2001852593 countsByYear W20018525932018 @default.
• W2001852593 countsByYear W20018525932019 @default.
• W2001852593 countsByYear W20018525932020 @default.
• W2001852593 countsByYear W20018525932021 @default.
• W2001852593 countsByYear W20018525932022 @default.
• W2001852593 countsByYear W20018525932023 @default.
• W2001852593 crossrefType "journal-article" @default.
• W2001852593 hasAuthorship W2001852593A5009015207 @default.
• W2001852593 hasAuthorship W2001852593A5025322230 @default.
• W2001852593 hasAuthorship W2001852593A5031391013 @default.
• W2001852593 hasAuthorship W2001852593A5038305710 @default.
• W2001852593 hasAuthorship W2001852593A5040884103 @default.
• W2001852593 hasAuthorship W2001852593A5044577073 @default.
• W2001852593 hasAuthorship W2001852593A5045859251 @default.
• W2001852593 hasAuthorship W2001852593A5047052496 @default.
• W2001852593 hasAuthorship W2001852593A5052353123 @default.
• W2001852593 hasAuthorship W2001852593A5060440062 @default.
• W2001852593 hasAuthorship W2001852593A5062656872 @default.
• W2001852593 hasAuthorship W2001852593A5064646828 @default.
• W2001852593 hasAuthorship W2001852593A5067487266 @default.
• W2001852593 hasAuthorship W2001852593A5068715327 @default.
• W2001852593 hasAuthorship W2001852593A5079789461 @default.
• W2001852593 hasAuthorship W2001852593A5089880898 @default.
• W2001852593 hasAuthorship W2001852593A5090199263 @default.
• W2001852593 hasConcept C111113717 @default.
• W2001852593 hasConcept C112705442 @default.
• W2001852593 hasConcept C126322002 @default.
• W2001852593 hasConcept C2776694085 @default.
• W2001852593 hasConcept C2778239845 @default.
• W2001852593 hasConcept C71924100 @default.
• W2001852593 hasConcept C98274493 @default.
• W2001852593 hasConceptScore W2001852593C111113717 @default.
• W2001852593 hasConceptScore W2001852593C112705442 @default.
• W2001852593 hasConceptScore W2001852593C126322002 @default.
• W2001852593 hasConceptScore W2001852593C2776694085 @default.
• W2001852593 hasConceptScore W2001852593C2778239845 @default.
• W2001852593 hasConceptScore W2001852593C71924100 @default.
• W2001852593 hasConceptScore W2001852593C98274493 @default.
• W2001852593 hasIssue "7" @default.
• W2001852593 hasLocation W20018525931 @default.
• W2001852593 hasLocation W20018525932 @default.

• next